- call +1-201-465-4211
- email sales@mrinsights.biz
The human immunodeficiency virus (HIV) refers to a type of retrovirus that causes acquired immunodeficiency syndrome (AIDS). HIV attacks some immune cells and causes weakness of immune system resulting in loss of ability to fight against the organism that causes disease.
Scope of the Report:
HIV spreads through fluidic exchange with some infected person such as blood transfer or sharing needles with someone who is HIV infected. In addition, HIV can spread from infected mother to child during pregnancy. Some of the symptoms of HIV infection are slight fever, fatigue, swollen glands, headaches and muscle aches.
HIV infection has no cure but there are treatments which help to stabilize or reduce this infection so that it does not lead to AIDS. HIV therapeutics market is growing at a significant rate due to increase in the HIV infected cases and growing awareness about the same. HIV infection can be treated by various therapeutics such as nucleoside/ nucleotide reverse transcriptase inhibitor, integrase inhibitor, HIV-1 protease inhibitor, non-nucleoside reverse transcriptase inhibitor, pharmacokinetic enhancer and entry inhibitor.
The global HIV Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of HIV Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the HIV Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the HIV Therapeutics market by product type and applications/end industries.
Market Segment by Companies, this report covers
Boehringer Ingelheim International GmbH
Merck & Co.
ViiV Healthcare
AbbVie
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Bristol-Myers Squibb
Gilead Sciences
Johnson & Johnson
Cipla Limited
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists
Market Segment by Applications, can be divided into
Hospitals
Clinics
Labs
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 HIV Therapeutics Market Overview
1.1 Product Overview and Scope of HIV Therapeutics
1.2 Classification of HIV Therapeutics by Types
1.2.1 Global HIV Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global HIV Therapeutics Revenue Market Share by Types in 2017
1.2.3 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
1.2.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
1.2.5 Entry and Fusion Inhibitors
1.2.6 Protease Inhibitors (PIs)
1.2.7 Integrase Inhibitors
1.2.8 Coreceptor Antagonists
1.3 Global HIV Therapeutics Market by Application
1.3.1 Global HIV Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Labs
1.4 Global HIV Therapeutics Market by Regions
1.4.1 Global HIV Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) HIV Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) HIV Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) HIV Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) HIV Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) HIV Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of HIV Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 Boehringer Ingelheim International GmbH
2.1.1 Business Overview
2.1.2 HIV Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Boehringer Ingelheim International GmbH HIV Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Merck & Co.
2.2.1 Business Overview
2.2.2 HIV Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Merck & Co. HIV Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 ViiV Healthcare
2.3.1 Business Overview
2.3.2 HIV Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 ViiV Healthcare HIV Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 AbbVie
2.4.1 Business Overview
2.4.2 HIV Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 AbbVie HIV Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 F. Hoffmann-La Roche Ltd.
2.5.1 Business Overview
2.5.2 HIV Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 F. Hoffmann-La Roche Ltd. HIV Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 Teva Pharmaceutical Industries Ltd.
2.6.1 Business Overview
2.6.2 HIV Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Teva Pharmaceutical Industries Ltd. HIV Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Bristol-Myers Squibb
2.7.1 Business Overview
2.7.2 HIV Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Bristol-Myers Squibb HIV Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.8 Gilead Sciences
2.8.1 Business Overview
2.8.2 HIV Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Gilead Sciences HIV Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.9 Johnson & Johnson
2.9.1 Business Overview
2.9.2 HIV Therapeutics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Johnson & Johnson HIV Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.10 Cipla Limited
2.10.1 Business Overview
2.10.2 HIV Therapeutics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Cipla Limited HIV Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global HIV Therapeutics Market Competition, by Players
3.1 Global HIV Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 HIV Therapeutics Players Market Share
3.2.2 Top 10 HIV Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global HIV Therapeutics Market Size by Regions
4.1 Global HIV Therapeutics Revenue and Market Share by Regions
4.2 North America HIV Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe HIV Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific HIV Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America HIV Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa HIV Therapeutics Revenue and Growth Rate (2013-2018)
5 North America HIV Therapeutics Revenue by Countries
5.1 North America HIV Therapeutics Revenue by Countries (2013-2018)
5.2 USA HIV Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada HIV Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico HIV Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe HIV Therapeutics Revenue by Countries
6.1 Europe HIV Therapeutics Revenue by Countries (2013-2018)
6.2 Germany HIV Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK HIV Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France HIV Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia HIV Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy HIV Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific HIV Therapeutics Revenue by Countries
7.1 Asia-Pacific HIV Therapeutics Revenue by Countries (2013-2018)
7.2 China HIV Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan HIV Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea HIV Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India HIV Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia HIV Therapeutics Revenue and Growth Rate (2013-2018)
8 South America HIV Therapeutics Revenue by Countries
8.1 South America HIV Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil HIV Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina HIV Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia HIV Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue HIV Therapeutics by Countries
9.1 Middle East and Africa HIV Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia HIV Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE HIV Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt HIV Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria HIV Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa HIV Therapeutics Revenue and Growth Rate (2013-2018)
10 Global HIV Therapeutics Market Segment by Type
10.1 Global HIV Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global HIV Therapeutics Market Forecast by Type (2018-2023)
10.3 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) Revenue Growth Rate (2013-2023)
10.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Revenue Growth Rate (2013-2023)
10.5 Entry and Fusion Inhibitors Revenue Growth Rate (2013-2023)
10.6 Protease Inhibitors (PIs) Revenue Growth Rate (2013-2023)
10.7 Integrase Inhibitors Revenue Growth Rate (2013-2023)
10.8 Coreceptor Antagonists Revenue Growth Rate (2013-2023)
11 Global HIV Therapeutics Market Segment by Application
11.1 Global HIV Therapeutics Revenue Market Share by Application (2013-2018)
11.2 HIV Therapeutics Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Clinics Revenue Growth (2013-2018)
11.5 Labs Revenue Growth (2013-2018)
12 Global HIV Therapeutics Market Size Forecast (2018-2023)
12.1 Global HIV Therapeutics Market Size Forecast (2018-2023)
12.2 Global HIV Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America HIV Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe HIV Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific HIV Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America HIV Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa HIV Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure HIV Therapeutics Picture
Table Product Specifications of HIV Therapeutics
Table Global HIV Therapeutics and Revenue (Million USD) Market Split by Product Type
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
